LSE - Delayed Quote GBp

AstraZeneca PLC (AZN.L)

11,988.00

-38.00

(-0.32%)

At close: 4:36 PM GMT+1

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.

Zacks 4 hours ago

AZN

SNY

NVS
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.

Zacks 6 hours ago

FUSN

AZN
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Investor's Business Daily 23 hours ago

AZN

SNY

CELG-RT
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.

Yahoo Finance yesterday

WXIBF

WXXWY

DSKYF
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.

Zacks yesterday

AZN
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump

Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump

PREMIUM
MT Newswires yesterday

AZN

CMCSA

IBM
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript

AZN earnings call for the period ending March 31, 2024.

Motley Fool yesterday

AZN
AstraZeneca reinforcing supply chain amid global tensions: CEO

AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its full-year guidance by claiming its "core EPS is expected to increase by a low double-digit to low teens percentage." To keep that guidance, the company bolstered its drug production, particularly in China, as uncertainty caused by geopolitical conflicts gave cause for concern. Shares of the pharmaceutical giant are rising on this news. AstraZeneca CEO Pascal Soriot joins Yahoo Finance Health Reporter Anjalee Khemlani to discuss AstraZeneca's performance, its production abilities, and future cancer treatments. "We are very much engaged in China, and we have been for many, many years. Having said that, of course, we have considered all this geopolitical tensions, and we have established a very resilient supply chain. We have manufacturing sites in China for China and some other countries in the emerging markets, in particular," Soriot speaks on the company's international ties. "Aand of course, we have a supply chain that is dedicated to what you might call the Western world — the US and Europe, for instance. We are right now in the process of building a cell therapy manufacturing site in Maryland. So, we really have a very resilient supply chain that has shown that it can sustain a crisis, and the COVID was a good example of this. " For more expert insight and the latest market action, click here to watch this full episode. This post was written by Nicholas Jacobino

Yahoo Finance Video yesterday

AZN

AZNCF
20 Fastest Growing Health Tech Companies in the World

In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]

Insider Monkey yesterday

TDOC

SNY

GSK
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Zacks yesterday

SNY

AZN
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion. This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines. The company’s adjusted EPADS reached $1.03, missing the consensus of $1.22. Also Read: AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost. R&D expenses rose a

Benzinga yesterday

AZN
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.

BioPharma Dive yesterday

AZN
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks yesterday

AZN
Cancer drugs help drive AstraZeneca sales sharply higher

Shares in the Cambridge-based company jumped by 5% in early trading.

PA Media: Money yesterday

AZN
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M

PR Newswire yesterday

AZN

AZNCF
Trending tickers: Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

The latest investor updates on stocks that are trending on Thursday.

Yahoo Finance UK yesterday

^IXIC

AZN

AZNCF
AstraZeneca Earnings, Sales Rise, Beat Forecasts

AstraZeneca reiterated its full-year guidance after posting first-quarter core earnings and sales above forecasts.

The Wall Street Journal yesterday

AZN

AZNCF
UPDATE 2-AstraZeneca trounces first-quarter estimates as resilient demand fuels growth

AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, underpinning strong demand for its blockbuster drugs and steady sales from partnered medicines. Oncology, the Anglo-Swedish drugmaker's top business, clocked a 26% jump in first-quarter sales to $5.12 billion. CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes.

Reuters yesterday

AZN
AstraZeneca leaps after smashing first-quarter forecasts

AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from partnered medicines and sending its shares up over 5%. Oncology, the Anglo-Swedish drugmaker's top business, delivered a 26% jump in first-quarter sales to $5.12 billion. CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, with blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes.

Reuters yesterday

AZN
Q1 2024 results

CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)

Business Wire yesterday

AZN

AZNCF

Performance Overview

Return	AZN.L	FTSE 100
YTD	+14.87%	+5.26%
1-Year	-0.32%	+3.15%
3-Year	+69.57%	+17.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZN.L)

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump

AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript

AstraZeneca reinforcing supply chain amid global tensions: CEO

20 Fastest Growing Health Tech Companies in the World

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say

Cancer drugs help drive AstraZeneca sales sharply higher

AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Trending tickers: Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca Earnings, Sales Rise, Beat Forecasts

UPDATE 2-AstraZeneca trounces first-quarter estimates as resilient demand fuels growth

AstraZeneca leaps after smashing first-quarter forecasts

Q1 2024 results

Performance Overview